Business Context and Reporting Period
This Form 8-K Current Report was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on June 25, 2020. The report details corporate governance actions taken following the Company's 2020 Annual Meeting of Stockholders held on the same date. The registrant is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is a reduction in the Company's authorized capital structure. Following shareholder approval, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, decreasing the number of authorized shares of common stock from 120,000,000 to 50,000,000. This amendment became effective on June 25, 2020.
Outlook, Management Commentary, and Voting Results
Management reported the results of three proposals voted upon at the Annual Meeting:
- Election of Directors: Thomas Hancock, Praveen Tyle, and Morton F. Goldberg, M.D. were elected as Class II Directors for a three-year term. All three nominees received significant support, with votes withheld ranging from approximately 29,000 to 47,000.
- Ratification of Auditors: Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020. The vote was 2,941,078 for, 33,961 against, and 59,425 abstained.
- Charter Amendment: Stockholders approved the reduction of authorized common shares. The vote was 2,801,359 for, 168,422 against, and 64,683 abstained.
The filing does not contain specific management commentary on future business outlook, risks, or contingencies beyond the procedural details of the meeting.
Investor Verification Checklist
- Verify the effective date of the Charter Amendment reducing authorized shares to 50,000,000.
- Confirm the terms of the newly elected Class II Directors (Thomas Hancock, Praveen Tyle, Morton F. Goldberg, M.D.) and their tenure until 2023.
- Review the full text of the Amendment to the Restated Certificate of Incorporation filed as Exhibit 3.1.
- Check subsequent filings for the Company's next financial report to assess liquidity and operational status, as this 8-K contains no financial data.